Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alliance Pharma's share price for the quarter that ended in Jun. 2023 was £0.4985. Alliance Pharma's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 540.2 Mil. Therefore, Alliance Pharma's market cap for the quarter that ended in Jun. 2023 was £269.3 Mil.
Alliance Pharma's quarterly market cap
declined
from Jun. 2022 (£616.4 Mil) to Dec. 2022 (£286.2 Mil) and
declined
from Dec. 2022 (£286.2 Mil) to Jun. 2023 (£269.3 Mil).
Alliance Pharma's annual market cap
increased
from Dec. 2020 (£466.8 Mil) to Dec. 2021 (£585.6 Mil) but then
declined
from Dec. 2021 (£585.6 Mil) to Dec. 2022 (£286.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alliance Pharma's Enterprise Value for Today is £287.2 Mil.
Alliance Pharma Market Cap Historical Data
The historical data trend for Alliance Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alliance Pharma's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alliance Pharma's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Alliance Pharma's Market Cap falls into.
Alliance Pharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Alliance Pharma's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alliance Pharma (LSE:APH) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Alliance Pharma Market Cap Related Terms
Thank you for viewing the detailed overview of Alliance Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:APH has been successfully added to your 